Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, New York. Guardant Health’s management is scheduled to participate in a fireside chat on Monday, September 11, at 11:20 a.m. Eastern Time / 8:20 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Inves

Haven Health Management, a leading provider of addiction and mental health treatment services across the United States, has announced the acquisition of Recovering Champions, an accredited drug and alcohol rehabilitation program based in Massachusetts. This strategic acquisition will expand Haven Health Management's comprehensive suite of services and further its mission to provide individualized care to patients across the nation. Recovering Champions is known fo

Verasonics, Inc., the leader in research ultrasound, today announced it will launch the Vantage NXT, the successor to Verasonics’ industry-leading Vantage Research Ultrasound System. The Vantage NXT Research Ultrasound System features a proprietary transceiver design that was specifically engineered to provide the next level of transmit and receive fidelity required for cutting-edge ultrasound research. Researchers will gain access to several enhancements including expanded frequency ba

Epineuron, a clinical-stage nerve care company, announced it has successfully enrolled the first patient in the company’s pivotal trial, REGAIN™. The multicenter, randomized, sham-controlled, double-blinded study is evaluating the safety and effectiveness of PeriPulse™, an investigational technology designated an FDA Breakthrough Device for the treatment of injured peripheral nerves. The study aims to enroll up to 110 patients across Canada and the United Stat

Thryve Digital Health, a leading provider of technology and operations expertise to some of the United States’ most prestigious integrated healthcare service networks, has extended its support to Aarohi Blood Center through its 'Thryve for Good' initiative. Thryve’s contributed a set of essential medical devices intended to enhance the Center’s capabilities—these included two blood bank refrigerators, a tube sealer, and a cell coagulometer. Aligned wi

Mainstay Medical Holdings plc today announced that it has completed enrollment in its RESTORE randomized clinical study of ReActiv8 for the treatment of stubborn chronic low back pain. The study is designed to provide a direct comparison with optimized medical management with the aim of testing the hypothesis that the addition of ReActiv8 reparative neurostimulation therapy to current care paradigms results in significant improvements in disability. related to back pain.

Hill Physicians Medical Group ("Hill Physicians"), California's largest independent physician association expands Medicare Advantage offerings in partnership with the Chinese Community Health Plan (CCHP). This means all existing CCHP Medicare Advantage members and consumers eligible for Medicare, can broaden their choice of physicians with the Hill Physicians Medical Group network. "We are pleased to offer the CCHP's Medicare Advantage plan which exp

Wellcare, the Medicare brand of Centene Corporation (NYSE: CNC), announced today a new strategic partnership with The American Legion, America's largest veterans service organization, during The American Legion's 104th National Convention in Charlotte, NC. Through the multi-year partnership, Wellcare will serve as the exclusive Medicare partner, connecting aged 65+ veterans, their spouses and the greater military community with innovative products and so

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference at the Sheraton New York. The fireside chat will take place on Monday, September 11, 2023, at 8:40 a.m. E

ML-007 was safe and well tolerated alone at all doses, including those that resulted in and exceeded anticipated clinically relevant exposures. When paired with the muscarinic antagonist, plasma ML-007 concentrations twelve times the minimum plasma target concentration were well tolerated, and an intolerable dose was not identified. No severe or serious adverse events were observed in the study. Importantly, multi-dose tolerability was comparable in elderly and healthy adult cohorts across al